Table 2.
Nanoagents | Imaging methods | Therapeutic effects | Ref |
---|---|---|---|
MnO2 NPs | MRI | Hypoxia relief; immunomodulation; Fenton reaction | 67 |
Gd-based NPs | MRI | Radio-sensitization; Gd-NCT | 100 |
AuNPs | PAI; CT; SERS | PTT; radiotherapy | 101 |
Iron oxide NPs | MRI; MPI | Ferroptosis; chemodynamic therapy; magnetic hyperthermia | 102 |
Other heavy metal oxide-based NPs | CT | PTT; radiotherapy | 103 |
Ag2S QDs | NIRF | PTT | 104 |
Polydopamine | Thermal image; PAI | PTT | 105 |
AIEgen | Photoluminescence imaging | PDT | 106 |
Theranostic radio-isotopes-labeled NP | SPECT or PET | Radiotherapy | 107 |
NPs: nanoparticles; Gd-NCT: gadolinium-neutron capture therapy; SERS: surface-enhanced Raman scattering; MPI: magnetic particle imaging; QDs: quantum dots; NIRF: near-infrared fluorescence; AIEgen: aggregation-induced emission luminogens; Theranostic radionuclides: 47Sc, 64Cu, 67Cu, 67Ga, 77As, 111In, 117mSn, 123I.